GLPBio

Signaling Pathways

Research Area, Signaling Pathways | GlpBio Life Science Products Suppliers

Read More about this category

The antibody-drug conjugate (ADC), a humanized or human monoclonal antibody conjugated with highly cytotoxic small molecules (payloads) through chemical linkers, is a novel therapeutic format and has great potential to make a paradigm shift in cancer chemotherapy. The three components of the ADC together give rise to a powerful oncolytic agent capable of delivering normally intolerable cytotoxins directly to cancer cells, which then internalize and release the cell-destroying drugs. At present, two ADCs, Adcetris and Kadcyla, have received regulatory approval with >40 others in clinical development.

ADCs are administered intravenously in order to prevent the mAb from being destroyed by gastric acids and proteolytic enzymes. The mAb component of the ADC enables it to circulate in the bloodstream until it finds and binds to tumor-specific cell surface antigens present on target cancer cells. Linker chemistry is an important determinant of the safety, specificity, potency and activity of ADCs. Linkers are designed to be stable in the blood stream (to conform to the increased circulation time of mAbs) and labile at the cancer site to allow rapid release of the cytotoxic drug. First generation ADCs made use of early cytotoxins such as the anthracycline, doxorubicin or the anti-metabolite/antifolate agent, methotrexate. Current cytotoxins have far greater potency and can be divided into three main groups: auristatins, maytansines and calicheamicins.

The development of site-specific conjugation methodologies for constructing homogeneous ADCs is an especially promising path to improving ADC design, which will open the way for novel cancer therapeutics.

References:

[1] Tsuchikama K, et al. Protein Cell. 2016 Oct 14. DOI:10.1007/s13238-016-0323-0.

[2] Peters C, et al. Biosci Rep. 2015 Jun 12;35(4). pii: e00225. doi: 10.1042/BSR20150089.

Research Areas

Products Related to Signaling Pathways(39732)

  • GN10088 structure
    GN10088Isoliquiritigenin
    CAS: 961-29-5
    Purity: >98.00%

    Isoliquiritigenin est un composé flavonoïde dérivé de la réglisse. Isoliquiritigenin active la voie Nrf2 pour réduire le stress oxydatif et l'inflammation, tout en inhibant la progression tumorale en induisant l'apoptose.

  • GN10091 structure
    GN10091Schaftoside
    CAS: 51938-32-0
    Purity: >99.50%
  • GN10093 structure
    GN100936-gingerol
    CAS: 23513-14-6
    Purity: >98.00%

    6-gingerol is an active compound isolated from Ginger with anticancer, anti-inflammation, and anti-oxidation activities.

  • GN10097 structure
    GN10097Wogonoside
    CAS: 51059-44-0
    Purity: >98.00%

    Wogonoside is a naturally occurring flavone glucuronide that inhibits α-glucosidase with an IC 50 value of18.25nM.

  • GN10098 structure
    GN10098Glabridin
    CAS: 59870-68-7
    Purity: >97.00%
  • GN10100 structure
    GN10100Sodium Danshensu
    CAS: 67920-52-9
    Purity: >98.00%
  • GN10103 structure
    GN10103Neferine
    CAS: 2292-16-2
    Purity: >99.50%

    Neferine (NEF) est un alcaloïde bisenzylisoquinoléine naturel isolé du médicament traditionnel chinois Nelumbinis plumula. Neferine possède diverses propriétés pharmacologiques.

  • GN10104 structure
    GN10104Gramine
    CAS: 87-52-5
    Purity: >98.00%
  • GN10107 structure
    GN10107Tubeimoside I
    CAS: 102040-03-9
    Purity: >98.00%
  • GN10109 structure
    GN10109Ganoderic Acid A
    CAS: 81907-62-2
    Purity: >98.00%

    Ganoderic Acid A est un composé triterpénoïd dérivé de Ganoderma lucidumand et exhibe de multiples activités biologiques.

  • GN10111 structure
    GN101115-hydroxymethyl-2-furaldehyde
    CAS: 67-47-0
    Purity: >99.00%
  • GN10112 structure
    GN10112Ginsenoside Rb2
    CAS: 11021-13-9
    Purity: >98.00%
  • GN10113 structure
    GN10113Cepharanthine
    CAS: 481-49-2
    Purity: >98.00%

    Cepharanthine, un alcaloïde bisbenzylisoquinoléine, possède une activité antivirale potentielle avec des valeurs d' EC50 de 0.15μM et 0.026μM pour SARS-CoV-2 et HIV-1, respectivement.

  • GN10114 structure
    GN10114Oroxin A
    CAS: 57396-78-8
    Purity: >98.00%
  • GN10115 structure
    GN10115Diosgenin
    CAS: 512-04-9
    Purity: >98.00%

    Diosgenin est une sapogénine stéroïdienne naturelle capable d'inhiber la voie de signalisation STAT3 et d'agir comme un activateur de Pdia3/ERp57, possédant ainsi diverses activités pharmacologiques importantes.

  • GN10116 structure
    GN10116Genipin
    CAS: 6902-77-8
    Purity: >98.00%

    Genipin est un inhibiteur spécifique de la protéine déouplante 2 (UCP2) extrait de Gardenia jasminoides Ellis.

  • GN10118 structure
    GN10118Desacetyl asperulosidic acid
    CAS: 14259-55-3
    Purity: >98.00%
  • GN10119 structure
    GN10119Zingerone
    CAS: 122-48-5
    Purity: >99.50%
  • GN10120 structure
    GN10120Pinocembrin
    CAS: 480-39-7
    Purity: >99.00%

    Pinocembrin est un composé flavonoïde et un inhibiteur compétitif de l'histidine décarboxylase (HDC).

  • GN10122 structure
    GN10122Linalool
    CAS: 78-70-6
    Purity: >98.00%
  • GN10123 structure
    GN10123Columbianadin
    CAS: 5058-13-9
    Purity: >98.00%
  • GN10126 structure
    GN10126Cytisine
    CAS: 485-35-8
    Purity: >98.00%
  • GN10127 structure
    GN10127Salidroside
    CAS: 10338-51-9
    Purity: >98.50%

    Salidroside est un glycoside tyrosol principalement trouvé dans les racines des espèces de Rhodiola, il exhibe un large éventail de propriétés biologiques et pharmacologiques, celles qui comprennent les effets anti-cancer, anti-oxydants, anti-âge, anti-diabétiques, anti-hypertensifs, anti-inflammatoires et immunomodulateurs.

  • GN10129 structure
    GN10129Polyphyllin VII
    CAS: 76296-75-8
    Purity: >98.00%